Chia-tai Tianqing Pharma Gains China Rights for Hepatitis C Drug from BioLineRx
publication date: Jun 10, 2013
Jiangsu Chia-tai Tianqing Pharmaceutical Co. in-licensed China rights to BL-8030, an oral treatment for hepatitis C virus, from BioLineRx, an Israeli clinical-stage pharma. CTTQ makes chemical drugs and TCM products, with liver disease a specialty for the company. BioLine will be eligible for up to $30 million in upfront and milestone payments. More details....
Stock Symbol: (NSDQ: BLRX); TASE: BLRX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.